Capricor Therapeutics will hold a phone meeting with the U.S. Food and Drug Administration (FDA) this month to discuss potential product registration…
Articles by Margarida Azevedo, MSc
An investigational therapy to treat congenital myotonic dystrophy, AMO-02 (tideglusib), has been granted fast track designation by the U.S. Food and…
The U.S. Food and Drug Administration (FDA), which in September 2016 approved Serepta Therapeutics’ Duchenne muscular dystrophy (DMD) treatment Exondys 51…
JAR of Hope, a foundation that funds Duchenne muscular dystrophy (DMD) research, is working to get legislation approved…
Santhera Pharmaceuticals has updated the timeline for the ongoing assessment by the European Committee for Medicinal Products for Human…
CureDuchenne has partnered with the Muscular Dystrophy Organization Nepal (MDON) to help deliver better care to Duchenne…
Summit Therapeutics has completed patient enrollment for PhaseOut DMD, a Phase 2 clinical trial evaluating the utrophin modulator ezutromid to treat …
The 7th Annual Getzlaf Golf Shootout to benefit CureDuchenne will take place Sept. 9 at Monarch Beach Golf Links in…
Japan has put Duchenne muscular dystrophy (DMD) drug candidate DS-5141b on its SAKIGAKE list, a designation to the U.S. Food and Drug Administration’s Fast…
The Duchenne muscular dystrophy (DMD) treatment Emflaza (deflazacort) was successfully acquired by PTC Therapeutics under terms agreed to in…